Skip to main content
. 2006 Sep;8(9):725–732. doi: 10.1593/neo.06388

Table 1.

ETA Receptor Antagonist and Docetaxel Treatment in Mice Bearing PPC-1 Xenograft Tumors.

Treatment Baseline Tumor (mm3) Final Tumor Volume (mm3) Doubling Time (mm3/day)
Vehicle 63.73 690.5 ± 165.0 5.93
ABT-627 54.58 775.5 ± 164.2 5.36
Docetaxel 55.57 657.4 ± 158.3 5.41
ABT-627 + docetaxel 55.1 321.7 ± 76.1* 8.29*
*

Statistically different from all other treatment groups (P < .05).